An Effectiveness and Safety Study Comparing Oxybutynin Chloride Plus FLOMAX (Tamsulosin HCl) and Placebo Plus FLOMAX (Tamsulosin HCl) for the Treatment of Lower Urinary Tract Symptoms.
Urination Disorders
About this trial
This is an interventional treatment trial for Urination Disorders focused on measuring lower urinary tract symptoms, DITROPAN XL, oxybutynin extended release tablets
Eligibility Criteria
Inclusion Criteria: Diagnosis of lower urinary tract symptoms with urgency and frequency with or without urge incontinence have had at least 4 weeks of 0.4 mg/day tamsulosin therapy an International Prostate Symptom Score (I-PSS) >=13 irritative component I-PSS score >= 8 max flow >= 8ml/sec with voided volume >= 125 ml, post-void residual volume <= 150 ml on two occasions. Exclusion Criteria: Clinically significant medical problems or other organ abnormality or pathology Prostate-Specific Antigen (PSA) >= 4 ng/ml history of inability to empty bladder completely or not at all uncontrolled narrow angle glaucoma history of any prostate surgery or treatment history of significant gastrointestinal problems.